ProQR Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions EUR

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for ProQR Therapeutics N.V. (PRQR) - Annual data in millions EUR
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-27.76-28.12-66.21-60.74-46.57-56.75-37.09
Depreciation & Amortization2.762.512.522.332.362.050.99
Deferred Income Tax-0.20-0.080.100.120.120.130.00
Stock Based Compensation2.543.112.876.227.840.000.00
Change in Working Capital-13.2648.96-5.4325.01-5.471.651.29
Change in Other Working Capital-0.54-6.011.6525.01-5.470.000.00
Other Operating Activities-0.67-6.012.871.47-5.54-0.400.79
Net Cash from Operating Activities-36.3921.55-68.51-26.01-47.06-43.97-28.49
Investing Activities
Capital Expenditures-1.42-1.370.71-0.48-0.92-0.58-0.31
Purchases of Investments-17.000.000.000.000.000.000.00
Sales/Maturities of Investments17.007.940.000.000.000.000.00
Other Investing Activities-2.66-2.350.000.000.000.000.00
Net Cash from Investing Activities-4.074.28-0.70-0.43-0.92-0.58-0.31
Financing Activities
Debt Repayment-1.58-2.63-1.67-0.82-0.61-1.260.00
Common Stock Issued71.860.3514.12110.000.7448.5584.19
Other Financing Activities0.220.001.392.790.000.000.00
Net Cash from Financing Activities70.28-2.28-30.89136.8314.5050.2086.46
Summary
Effect of Forex Changes on Cash0.670.607.351.29-2.630.72-0.17
Net Change in Cash30.4823.55-100.10111.69-36.115.6557.65
Cash at Beginning of Period118.9394.78187.5275.84111.95105.5848.10
Cash at End of Period149.41118.9387.42186.0275.84111.95105.58
Free Cash Flow-37.8120.18-69.21-26.50-47.98-44.55-28.81
Supplemental Disclosures
Interest Paid0.770.793.762.251.110.000.00
Income Taxes Paid-0.20-0.080.100.120.190.000.00